44-301 : Special Drug Use-Results Survey of VELEXBRU (PCNSL)
Not Applicable
- Conditions
- relapsed or refractory primary central nervous system lymphoma (PCNSL)
- Registration Number
- JPRN-jRCT2011210002
- Lead Sponsor
- Kuro Toshihiko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
All patients with PCSNL for whom VELEXBLU is administered
Exclusion Criteria
patients who have not received VELEXB
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety<br>Specified safety concerns: Infections,Severe skin disorders, Myelosuppression, Hypersensitivity, Interstitial lung diseases, Hepatic function disorders, Hemorrhage
- Secondary Outcome Measures
Name Time Method